Assessment of Health-Related Quality of Life and Drug Therapy Management in Women with Polycystic Ovarian Syndrome

Background: Polycystic Ovarian Syndrome (PCOS) is the most common metabolic disorder that adversely affects the quality of life (QoL) of women of reproductive age. PCOS symptoms can be actively controlled with medications and lifestyle modifications. The present study aims to assess the signs and symptoms of QoL and drug therapy management. Methods A prospective descriptive study was conducted among 137 patients for a duration of 6 months. A patient data collection form was documented, and details regarding the treatment given to the patients were noted. To determine if PCOS had a negative impact on QoL, PCOSQ was administered to the patients. Statistical analysis was performed using SPSS (version.20.0) Results A total of 137 patients were included in the study, the majority of whom were in the age group of 21–25 years, 73 (53.3%), and had a normal BMI, 48 (35%). Menstrual cramps were prevalent in 87.59% of the patients, making it the most common symptom. Cyproterone and Ethinyl Estradiol 33 (15.50%) were the most commonly used drugs among these patients. PCOSQ results obtained from our study indicated that menstrual problems were the most affected domain. Few other comparisons, such as HRQoL domain scores with age and BMI, determined that there was a significant difference between the age group and QoL domains. Comparison of HRQoL with clinical presentations indicated that there was a negative impact on all five domains with weight and weakness. Conclusion The study concluded that there was a positive association of QoL deterioration with worsening signs and symptoms.